Cell therapy

Class

Cell therapy (allogeneic, cord-blood-derived, non-genetically-modified NK cells)

Pathway

Antibody-dependent cellular cytotoxicity enhancement in combination with anti-CD20 monoclonal antibody

Notes

original target text: Cell therapy (allogeneic, cord-blood-derived, non-genetically-modified NK cells)

This mechanism describes a cellular therapy built on natural killer (NK) cells — cytotoxic lymphocytes of the innate immune system that kill abnormal or infected cells without requiring prior antigen exposure. The cells used here are allogeneic (sourced from a donor, not the patient) and derived from umbilical cord blood, then expanded without genetic modification. Because they are unmodified, their killing capacity depends heavily on how they are directed toward a specific tumor.

The rationale for pairing these NK cells with an anti-CD20 monoclonal antibody rests on antibody-dependent cellular cytotoxicity (ADCC): the antibody binds CD20, a surface marker on B lymphocytes and many B-cell cancers, coating tumor cells with antibody. NK cells recognize the exposed antibody tail through a surface receptor and are triggered to release cytotoxic granules that destroy the coated cell. Supplying additional, functionally intact donor NK cells is intended to compensate for the reduced number or activity of a patient's own NK cells, which is common after chemotherapy or in advanced cancer, thereby amplifying the antibody's tumor-killing effect. This approach is broadly relevant to B-cell malignancies such as lymphomas and leukemias that express CD20.